Text Size

Current and Future Treatment of Retinitis Pigmentosa

Cross N, van Steen C, Zegaoui Y, Satherley A, Angelillo L.


  • 2022
  • Clin Ophthalmol
View publication
  • Therapeutic Area

    Back of the eye (BOTE)

  • Technology

    Gene / Cell Therapy

  • Categories

    Disease understanding (epidemiology, diagnosis, QoL, Biomarkers…)

  • Affiliations

    Market Access, Lightning Health, London, UK.; Market Access, Health Technology Assessment & Health Economics and Outcome Research, Europe, the Middle East and Africa, Santen GmbH, Munich, Bavaria, Germany

Related Publications

Consensus on evidence gaps and unmet needs in childhood myopia: findings from a European Delphi study with eye care professionals and payers

Lagreze W, Nucci P, Versteegh M, Klaver C, Barrio-Barrio J, Dahlmann-Noor A, Gomez de Liaño R, Ghorbani-Mojarrad N, Kessel L, Polling JR, Sauer A, Schuster AK, Serafino M, Villani E, Ziemssen F, Boehler YB, Capri S, Gianfrate F, Valles Callol JA, Wong O, Chen TY, Lymperopoulou C, Palaka I, Punekar Y, von Bredow D, Shi-van Wielink K.


Economic evaluation, resource utilisation, and associated economic burden of myopia management: a systematic literature review

de Milliano T. WL, Shi-van Wielink K., Ernst F., Mulkalapalli N., Pagidigummula R., Lymperopoulou C.


Efficacy and Safety of Low-Concentration Atropine in Slowing Myopia Progression in Children in Japan: The Randomized, Double-Blind Phase II/III ORANGE Study

Ohno-Matsui K., Igarashi-Yokoi T., Migita Y., Yamakawa Y, on behalf of the ORANGE study investigators


Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022